Fig. 3.

CX3CR1⁺ CD8⁺ T cells are dispensable for the antitumor efficacy of neoantigen/TLR3/CD40 agonists vaccination against established tumors. a Schematic illustration showing evaluation of in vivo antitumor efficacy of the CX3CR1⁺ subset using MC38 tumor-bearing Cd2-cre/Cx3cr1^+/DTR mice treated with Adpgk^Mut/TLR3/CD40 agonists vaccination (Vac) followed by diphtheria toxin (DT) administration. DT (250 ng) was injected intraperitoneally every day from day 13. b Representative FACS plots showing selective depletion of CX3CR1⁺ subset in PB upon DT injection in Cd2-cre/Cx3cr1^+/DTR mice treated with Vac. Expression of CX3CR1 in CD8⁺ T cells in PB of mice treated with PBS or DT is shown. Numbers denote percentage of the CX3CR1⁺ subset. c Tumor growth and survival curves of MC38 tumor-bearing Cd2-cre/Cx3cr1^+/DTR mice in different treatment groups. (n = 8 mice per group). Data shown are representative from two independent experiments. NS not significant, ***P < 0.001, log-rank test (c). Mean ± SEM